Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
Oral paclitaxel bests IV version for tumor response, neuropathy incidence in mBC
Publish date:
December 19, 2019
REPORTING FROM SABCS 2019
SOURCE:
Umanzor G et al. SABCS 2019, Abstract
GS6-01
.
Pages
« first
1
2
Recommended Reading
APHINITY 6-year data: Benefit ongoing in HER2+ early BC, no significant OS benefit
MDedge Hematology and Oncology
Promising new neoadjuvant strategy in luminal B breast cancer
MDedge Hematology and Oncology
Pembrolizumab plus chemo boosts pCR rate in TNBC
MDedge Hematology and Oncology
TNBC: Adding capecitabine boosts disease-free survival in prospective trial
MDedge Hematology and Oncology
Residual cancer burden linked to long-term survival
MDedge Hematology and Oncology
CTS5 score partially validated for predicting late distant breast cancer recurrences
MDedge Hematology and Oncology
ctDNA, CTCs predict TNBC relapse – now what?
MDedge Hematology and Oncology
First report from NeoTRIPaPDL1: No pCR benefit with atezolizumab in TNBC
MDedge Hematology and Oncology
TNBC: Weekly nab-paclitaxel delivers, denosumab disappoints
MDedge Hematology and Oncology
PEARL lacks luster in metastatic breast cancer progressing on AIs
MDedge Hematology and Oncology
Breast Cancer
All Specialties
